Head-to-head · WeighScore
9amHealth vs Omada Health
The verdict
9amHealth takes it — 71.3/100 to 55.6/100.
9amHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. 9amHealth (join9am.com) is a cardiometabolic telehealth platform offering whole-body care including weight management with FDA-approved branded GLP-1 medications such as Wegovy, Zepbound, and Saxenda, plus…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | 9amHealth | Omada Health |
|---|---|---|
| WeighScore | 71.3/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #93 | #435 |
| Semaglutide | $149/mo (plus a separate fee, brand-name) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #93 · C
Strengths
- Prescribes FDA-approved branded GLP-1s (Wegovy, Zepbound, Saxenda)
- $149/month membership or free when covered by insurance
- Membership includes specialists, labs, devices, and medications
- Board-certified obesity specialists (DABOM), endocrinologists, dietitians, PharmDs
- Helps navigate insurance approvals; employer and state-plan partnerships
Where it loses points
- Medication coverage and GLP-1 access depend on insurance and BMI criteria
- State availability not enumerated on the public site
- Branded GLP-1s can be costly without insurance coverage
- Pricing for medications not transparently listed
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.